Your browser doesn't support javascript.
loading
Influence of the Short-term Intake of High Doses of Solifenacin and Trospium on Cognitive Function and Health-Related Quality of Life in Older Women With Urinary Incontinence.
Kosilov, Kirill; Kuzina, Irina; Loparev, Sergay; Gainullina, Yuliya; Kosilova, Liliya; Prokofyeva, Alexandra.
Afiliação
  • Kosilov K; Department of Social Sciences, School of Humanities, Far Eastern Federal University, Vladivostok, Russian Federation.
  • Kuzina I; Department of Social Sciences, School of Humanities, Far Eastern Federal University, Vladivostok, Russian Federation.
  • Loparev S; Department of Urology, City polyclinic No. 3, Vladivostok, Russian Federation.
  • Gainullina Y; Department of Social Sciences, School of Humanities, Far Eastern Federal University, Vladivostok, Russian Federation.
  • Kosilova L; Department of Functional Diagnostics, Med. Association No. 2 of Vladivostok, Vladivostok, Russian Federation.
  • Prokofyeva A; Department of Social Sciences, School of Humanities, Far Eastern Federal University, Vladivostok, Russian Federation.
Int Neurourol J ; 22(1): 41-50, 2018 Mar.
Article em En | MEDLINE | ID: mdl-29609422
PURPOSE: The aim of this study was to investigate the safety and the effects of elevated doses of solifenacin and trospium on cognitive function and health-related quality of life (HRQoL) in elderly women receiving treatment for urinary incontinence. METHODS: The study included 312 women aged 60-83 years (mean age, 69.4 years). All participants had scored at least 24 points on the Mini-Mental State Examination (MMSE) scale, and all of them had been diagnosed with urge urinary incontinence (UUI) or mixed urinary incontinence (MUI). The women were randomly assigned to 3 groups: group A, individuals who were simultaneously administered solifenacin at a high dosage of 20 mg per day and trospium at a high dosage of 60 mg per day; group B, persons taking solifenacin and trospium at the usual dosage of 10 and 30 mg per day, respectively; and group C, persons who received a placebo. Participants' cognitive status was assessed by the MMSE, Controlled Oral Word Association Test, Wechsler Adult Intelligence Scale-Revised, Wechsler Memory Scale III, Colour Trails Test, and California Verbal Learning Test scales. The HRQoL assessment was performed using the Medical Outcomes Study 36-Item Health Survey. RESULTS: The cognitive function parameters did not differ at the start and end of the study across the groups (P>0.05). Additionally, the cognitive function parameters did not differ significantly within each group between the start and end of the study (P>0.05). The values of most HRQoL parameters regarding the functional state of the lower urinary tract (LUT) after the termination of treatment significantly improved in groups A and B (P<0.05). A significant correlation between cognitive status and HRQoL or LUT parameters was absent (r<0.3), while the correlations between HRQoL and LUT parameters were r=0.31-0.83, P<0.05. CONCLUSIONS: The use of elevated doses of solifenacin and trospium did not increase the risk of cognitive impairment in women with UUI and MUI. The combination of solifenacin and trospium at a double dosage may be recommended to elderly women with treatment-resistant symptoms of UUI and MUI. However, the safety of combining antimuscarinic drugs in women with an increased volume of residual urine requires further study.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Aspecto: Patient_preference Idioma: En Revista: Int Neurourol J Ano de publicação: 2018 Tipo de documento: Article País de publicação: Coréia do Sul

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Aspecto: Patient_preference Idioma: En Revista: Int Neurourol J Ano de publicação: 2018 Tipo de documento: Article País de publicação: Coréia do Sul